Form 4: Arrowhead Pharmaceuticals Director Acquires Shares Through Restricted Stock Units

Director William D. Waddill acquired 16,733 shares of Arrowhead Pharmaceuticals through restricted stock units.

Summary

• William D. Waddill, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock on December 18, 2024.
• The shares were acquired through restricted stock units at a price of $22.99 per share.
• These restricted stock units will vest in one installment on the first anniversary date.
• Following the transaction, Mr. Waddill beneficially owns 57,111 shares of Arrowhead Pharmaceuticals.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction by a company director, which is generally neutral to slightly positive as it indicates confidence in the company. There is no indication of any negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders when they make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this transaction is consistent with typical insider trading activity.
• The acquisition of shares through restricted stock units is a common form of compensation for directors and executives in the pharmaceutical industry.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it indicates a director's confidence in the company.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Director, Stock Acquisition, Restricted Stock Units, ARWR, Beneficial Ownership